Ultragenyx, Mereo crash on late-stage bone disease failure

The rare bone disease drug being developed by Ultragenyx Pharmaceutical and Mereo BioPharma has categorically failed in its late-stage program, the partners revealed Monday. Mereo’s stock {$MREO} fell 90% when the Nasdaq opened on Monday ...